Neurana Pharmaceuticals, a biotechnology company, has been revolutionizing the treatment of acute muscle spasms since its establishment in 2013. The California-based company has attracted significant attention, securing a noteworthy $60.00M Series A investment on 08 May 2018 from a group of prominent investors including H.I.G. BioHealth Partners, Longitude Capital, New Leaf Venture Partners, Sofinnova Investments, and MagnaSci Ventures. Specializing in the Biotechnology, Health Care, and Pharmaceutical sectors, Neurana Pharmaceuticals is committed to developing an innovative solution for acute muscle spasms, displaying considerable promise for the future of medical treatment.
No recent news or press coverage available for Neurana Pharmaceuticals.